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Post-synaptic congenital myasthenic syndromes (CMSs) (OMIM_ #608931) is a group of genetic 
disorders affecting neuromuscular transmission and due to acetylcholine receptor (AChR) 
deficiency in 80% of cases.[1] These autosomal recessive CMSs may be caused by mutations in 
genes encoding the AChR or one of the AChR-clustering or anchoring proteins, rapsyn, Dok-7 or 
MuSK.[1-4] Spectra of rapsyn mutations show allelic heterogeneity and suggest that the common 
substitution p.Asn88Lys (N88K)  (variant_021217 in Q13702) results in less stable AChR 
clusters.[5] Until recently, all patients harbouring mutations in RAPSN are either homozygous for 
the p.Asn88Lys substitution or heteroallelic for p.Asn88Lys and a mutation which is in most of 
cases an amino acid substitution but can be also a null allele.[6] Analysis of disease severity in 
patients suggested that the second mutant allele may largely determine severity of the 
phenotype.[7] Recently, a patient with two non p.Asn88Lys in RAPSN has been described and 
the first chromosomal deletion event was described by Müller and colleagues.[8,9]  
When analysing 20 patients presenting recessive CMS for RAPSN mutations three out of 
them were carriers of different large (multi-exonic) but partial deletions of RAPSN that could not 
be identified by gene sequencing.  
Patient 1 is a 22-year-old girl presenting a severe generalized hypotonia at birth with 
arthrogryposis, retrognathism and amimic face with no sucking reflex. There was no respiratory 
problem or dysphagia. She achieved independent walking on tiptoes at 16 months and presented 
several episodes during which she was unable to walk. At age 17, she showed a mild proximal 
muscle weakness in the four limbs and in neck flexors, a reduced mouth opening and a slight 
limitation in left eye abduction. EMG demonstrated a clear decrement on 3-Hz repetitive 
stimulation in trapezius and quadriceps muscles.  
Patient 2 is a 27-year-old woman presenting a severe generalized hypotonia at birth with 
arthrogryposis of the ankles, knees, elbows, and fingers. She had facial diplegia, respiratory 
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failure with weak cries, no suction, no swallowing, and a permanent defect of orbicular muscles 
of lips and eyes. The diagnosis of CMS was confirmed after a negative test for AChR antibodies, 
a 15% decrement and a positive prostigmine test.  
Patient 3 is a 7-years-old girl with no family history. At birth, a major hypotonia and 
arthrogryposis of the hands and feet were noted. She was not able to swallow and had frequent 
respiratory failure episodes leading to mechanical ventilation. The prostigmine test was positive 
and the EMG showed a decrement confirming the diagnosis of CMS.  
Molecular analyses revealed in Patient 1, an “apparently” homozygous RAPSN substitution 
(c.264c>a), p.Asn88Lys transmitted by the unaffected mother but not carried by the father 
suggesting a “missed” variant not detected by usual sequencing approach.  
In both Patients 2 and 3, the missense p.Asn88Lys substitution was identified on a single allele 
with no identification of the second allelic mutation. In both families, heterozygous parent for 
p.Asn88Lys was the mother. We determined the RAPSN copy number in each patient, using three 
SNPs known to cosegregate (rs7111873, rs34729771 and rs7126210; fig 1). In these three 
patients, the SNPs do not cosegregate correctly. In patient 1, rs34729771 and rs7126210 SNPs 
were heterozygous while rs7111873 was homozygous. In patient 2, only the SNPs rs7111873 
was heterozygous. In patient 3, only rs7111873 and rs34729771 were heterozygous. A relative 
quantification for each exon of RAPSN was performed by a qPCR approach. In patient 1, a 
deletion involving 5’UTR, promoter, exon 1 and exon 2 was detected (fig 2). Partial delimitation 
of breakpoints showed that the deletion corresponding to a ~30kb occurred between rs2242081 
and intron 2. In patient 2, allelic quantification confirms the loss of exon 3 to 7 on one allele and 
the long range PCR/sequencing showed that the recombination occurred between a short 
sequence of 7 nucleotides (CCTGCAG) in intron 2 at the junction with exon 3 (c.532-7; c.532-1) 
and the same sequence at the 5’ end of exon 8 (c.1170_1176) resulting in a deletion spanning on 
4.785 kb (g.47,416,165_47,420,949del). In patient 3, the deletion involves exon 7 to 8 and part of 
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3’UTR and the recombination occurred between two sequences of 25 nucleotides 
(GCTAATTTTTGTATTTTTAGTAGAG), the first located in intron 6 (c.967-398_967-374) and 
the other one located in 3’UTR region resulting in a deletion of 10.334 kb (g. 
47,417,456_47,407,123del). The allele quantification was performed in the parents and showed 
that in the 3 families, the chromosomal micro-deletion was transmitted by the father (for 
experimental details see Supplemental data files 1 and 2).  
In our series of CMS patients recruited via the French CMS National Network, twenty 
patients were found with disease-causing mutations in RAPSN. Among these patients, three 
(15%) had the recurrent p.Asn88Lys substitution but the sequencing approach failed to identify 
the second allelic mutation. We hypothesized that genomic deletions may account in these 
patients and developed a simple molecular assay based on qPCR analysis. This led us to identify 
three different chromosomal micro-deletions due to recombinations. All these multi-exon 
deletions corresponded to the missing disease-causing allelic mutation in patients.  
 The description of Müller and colleagues and ours demonstrates that RAPSN, containing 
numerous repeated sequences, is particularly subject to multiple genomic recombinations. The 
precise deletions breakpoints determination showed that the recombination involves multiple and 
different sequences in all the described cases. 
 Altogether these findings lead to the following comments: (i) a negative result obtained 
by direct sequencing of genomic DNA raises the question of an incomplete detection of some 
mutations; (ii) in recessive transmissions, the analysis of patient parents is crucial to confirm the 
inheritance; (iii) phenotype-genotype correlations should also be considered:while patient 1 did 
not exhibit a very severe phenotype during childhood, patients 2 and 3 presented a CMS with all 
criteria of severity corresponding to the phenotype observed in patients carrying the p.Asn88Lys 
substitution associated with another allelic mutation.[10]  
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 In conclusion, this mutational mechanism represents 15% of patients with RAPSN 
mutations referred to our laboratory.  For diagnostic purposes, carrier detection, genetic 
counselling, and prenatal diagnosis, it is critical to know the exact functional gene copy number 
that an individual carries.  
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 Figure legends:  
 
Figure 1: Schematic representation of RAPSN. Exons are numbered from 1 to 8. The common 
p.Asn88Lys substitution and the three known allelic SNPs are indicated by arrows. Presence or 
absence of these polymorphisms for the three patients is indicated: presence of the SNP 
heterozygous (+);  absence of the SNP (-).  
 
Figure 2:  Graphic representation of the relative quantification of RAPSN exons. Results were 
expressed in N-fold changes in RAPSN exon copies, normalized to β-globin relative to the copy 
number of the target gene. When 0.8 <N-fold< 1.7, the DNA sample harboured two copies of the 
RAPSN exon. If N-fold was <0.7, the sample harboured only one copy of the exon. qPCR in 
patients revealed a clear reduction to about 50% for the deleted exons, exon 1 and 2 in patient 1, 
exons 3 to 7 in patient 2 and exons 7 and 8 in patient 3. 
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